Cancer Biology Seminar Series: Dave Vereide, PhD

This event has passed.

1345 HSLC
@ 11:00 am - 12:00 pm

Arming induced pluripotent stem cells with a synthetic receptor enables the scalable manufacture of highly cytotoxic lymphocytes for “off-the-shelf” cancer immunotherapies
Dave Vereide, PhD
Principal Scientist
Umoja Biopharma